Beiersdorf has managed to stay in line with its expectations in the first nine months of the year, reaching group sales of €7.5 billion, with organic growth of 2 %, thanks to the strong performance of its Derma division.
The Consumer Business segment recorded sales of €6.3 billion, also with organic growth of 2 %, driven by brands such as Eucerin and Aquaphor, which continue to gain market share globally. For its part, NIVEA grew by 0.6 %, with good initial results after the launch of its NIVEA Cellular Epigenetics Serum with Epicelline®, while La Prairie, after a 7.2 % drop in the period, resumed growth in the third quarter.
The Health Care business (Hansaplast and Elastoplast) grew by 8.8 %, driven by innovations in wound care, and tesa reached €1.3 billion in sales, with an increase of 2 %, led by its Electronics unit in Asia-Pacific.
The CEO of Beiersdorf, Vincent Warnery, highlighted that the company continues to reinforce its strategy based on innovation and portfolio adjustments: “The success of Derma demonstrates that we can outperform the competition and generate solid growth. At NIVEA, our new innovations and the expansion of the portfolio in skin care and deodorants will strengthen the brand in the long term.”
The company adjusted its guidance for 2025, anticipating organic growth of 2.5 % in the Consumer Business and 1–3 % in tesa, while the group’s EBIT margin would remain slightly above the 2024 level.
